CO6270229A2 - Derivados de tiazol fusionados como inhibidores de quinasa - Google Patents

Derivados de tiazol fusionados como inhibidores de quinasa

Info

Publication number
CO6270229A2
CO6270229A2 CO09149835A CO09149835A CO6270229A2 CO 6270229 A2 CO6270229 A2 CO 6270229A2 CO 09149835 A CO09149835 A CO 09149835A CO 09149835 A CO09149835 A CO 09149835A CO 6270229 A2 CO6270229 A2 CO 6270229A2
Authority
CO
Colombia
Prior art keywords
fusionated
derivatives
tiazol
inhibitors
quinasa
Prior art date
Application number
CO09149835A
Other languages
English (en)
Spanish (es)
Inventor
Rikki Peter Alexander
Pavandeep Singh Aujla
Karen Viviane Crepy
Anne Marie Foley
Richard Jeremy Franklin
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0612644A external-priority patent/GB0612644D0/en
Priority claimed from GB0620062A external-priority patent/GB0620062D0/en
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of CO6270229A2 publication Critical patent/CO6270229A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CO09149835A 2006-06-26 2009-12-31 Derivados de tiazol fusionados como inhibidores de quinasa CO6270229A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0612644A GB0612644D0 (en) 2006-06-26 2006-06-26 Therapeutic agents
GB0620062A GB0620062D0 (en) 2006-10-10 2006-10-10 Therapeutic agents
PCT/GB2007/002390 WO2008001076A1 (en) 2006-06-26 2007-06-26 Fused thiazole derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
CO6270229A2 true CO6270229A2 (es) 2011-04-20

Family

ID=38671000

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09149835A CO6270229A2 (es) 2006-06-26 2009-12-31 Derivados de tiazol fusionados como inhibidores de quinasa

Country Status (20)

Country Link
US (3) US8242116B2 (enExample)
EP (2) EP2035436B1 (enExample)
CN (1) CN101687885B (enExample)
AT (1) ATE510840T1 (enExample)
AU (1) AU2008269577B2 (enExample)
CA (1) CA2692085C (enExample)
CO (1) CO6270229A2 (enExample)
CY (1) CY1114419T1 (enExample)
DK (1) DK2170906T3 (enExample)
EA (1) EA017187B1 (enExample)
ES (2) ES2365258T3 (enExample)
HR (1) HRP20130523T1 (enExample)
IL (1) IL202659A0 (enExample)
ME (1) ME01592B (enExample)
MX (1) MX2009013740A (enExample)
MY (1) MY148852A (enExample)
PL (1) PL2170906T3 (enExample)
PT (1) PT2170906E (enExample)
RS (1) RS52824B (enExample)
WO (1) WO2008001076A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009071895A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Fused thiazole and thiophene derivatives as kinase inhibitors
WO2009071890A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Tricyclic kinase inhibitors
AU2008343932B2 (en) 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
ATE531372T1 (de) 2008-04-07 2011-11-15 Amgen Inc Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren
JPWO2009130900A1 (ja) * 2008-04-24 2011-08-11 日本曹達株式会社 オキシム誘導体、中間体化合物および植物病害防除剤
US8603945B2 (en) * 2008-07-23 2013-12-10 The Regents Of The University Of California Methods and compositions for providing salicyclic acid-independent pathogen resistance in plants
EP2341052A4 (en) * 2008-09-05 2011-10-12 Shionogi & Co RING-CONDENSED MORPHOLINE DERIVATIVITY WITH PI3K-INHIBITING EFFECT
CA2752596A1 (en) 2009-02-17 2010-08-26 Vertex Pharmaceuticals Incorporated Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase
JP2012520887A (ja) * 2009-03-18 2012-09-10 シェーリング コーポレイション ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
ES2638323T3 (es) 2009-05-20 2017-10-19 Glaxosmithkline Llc Derivados de tiazolopirimidinona como inhibidores de PI3 quinasa
GB0912946D0 (en) 2009-07-24 2009-09-02 Addex Pharmaceuticals Sa New compounds 5
NZ597983A (en) 2009-08-20 2014-05-30 Karus Therapeutics Ltd Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
AU2010332819B2 (en) * 2009-12-18 2014-02-27 Janssen Pharmaceutica Nv Bicyclic thiazoles as allosteric modulators of mGluR5 receptors
EP2513117B1 (en) 2009-12-18 2013-08-28 Janssen Pharmaceutica, N.V. Bicyclic thiazoles as allosteric modulators of mglur5 receptors
EP2582693B1 (de) 2010-06-15 2016-03-30 Bayer Intellectual Property GmbH Neue ortho-substituierte arylamid-derivate
EP2621897A1 (en) 2010-10-01 2013-08-07 Basf Se Imine compounds
MX2013004003A (es) * 2010-10-13 2013-10-01 Millenium Pharmaceuticals Inc Heteroarilos y usos de los mismos.
BR112013012961A2 (pt) * 2010-11-24 2019-09-24 Exelixis Inc benzoxazepinas como inhibidores de mtor e métodos de seu uso e fabricação
CN102649777B (zh) * 2011-02-25 2014-03-12 中国中化股份有限公司 一种制备1-芳基-3-羧基-5-吡唑啉酮类化合物的方法
KR101606250B1 (ko) 2011-03-23 2016-03-24 암젠 인크 Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
IN2014CN04174A (enExample) 2011-12-22 2015-09-04 Novartis Ag
EP2970135B1 (en) 2013-03-14 2018-07-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
CA2903394C (en) 2013-03-14 2021-08-31 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP3363434A1 (en) 2013-03-14 2018-08-22 Epizyme Inc Arginine methyltransferase inhibitors and uses thereof
EP2970181B1 (en) 2013-03-14 2017-06-07 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153172A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9394258B2 (en) 2013-03-14 2016-07-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9133189B2 (en) 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
JP2016514164A (ja) 2013-03-14 2016-05-19 エピザイム，インコーポレイティド アルギニンメチルトランスフェラーゼ阻害剤としてのピラゾール誘導体およびその使用
US20160039767A1 (en) 2013-03-14 2016-02-11 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
KR102456277B1 (ko) * 2013-10-21 2022-10-18 우미코레 아게 운트 코 카게 방향족 아민의 모노아릴화
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201514754D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN108570043A (zh) * 2018-06-20 2018-09-25 王延娇 一种化合物及其作为选择性pi3k抑制剂在治疗肿瘤中的应用
US20220202824A1 (en) 2018-09-13 2022-06-30 Stemline Therapeutics, Inc. Methods for Treating Centronuclear Myopathy
MX2021006421A (es) 2018-12-19 2021-08-16 Leo Pharma As Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
JP7575952B2 (ja) * 2019-01-08 2024-10-30 杏林製薬株式会社 １５－ｐｇｄｈ阻害薬
WO2020160151A1 (en) 2019-01-31 2020-08-06 Kyorin Pharmaceutical Co., Ltd. 15-pgdh inhibitors
GB201909468D0 (en) 2019-07-01 2019-08-14 Karus Therapeutics Ltd Compounds for treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0508471D0 (en) 2005-04-26 2005-06-01 Celltech R&D Ltd Therapeutic agents

Also Published As

Publication number Publication date
PT2170906E (pt) 2013-06-25
CY1114419T1 (el) 2016-08-31
PL2170906T3 (pl) 2013-08-30
US20100137302A1 (en) 2010-06-03
US20110003785A1 (en) 2011-01-06
IL202659A0 (en) 2010-06-30
AU2008269577A1 (en) 2008-12-31
EP2170906B1 (en) 2013-04-03
US8242116B2 (en) 2012-08-14
US8338592B2 (en) 2012-12-25
ME01592B (me) 2014-09-20
EP2035436B1 (en) 2011-05-25
ES2365258T3 (es) 2011-09-27
RS52824B (enExample) 2013-10-31
US8710054B2 (en) 2014-04-29
EP2170906A1 (en) 2010-04-07
WO2008001076A1 (en) 2008-01-03
DK2170906T3 (da) 2013-06-24
MY148852A (en) 2013-06-14
CA2692085C (en) 2015-10-13
HRP20130523T1 (en) 2013-07-31
EA201000038A1 (ru) 2010-06-30
US20130079330A1 (en) 2013-03-28
CN101687885A (zh) 2010-03-31
CN101687885B (zh) 2012-08-22
ATE510840T1 (de) 2011-06-15
MX2009013740A (es) 2010-02-01
AU2008269577B2 (en) 2012-12-20
EP2035436A1 (en) 2009-03-18
CA2692085A1 (en) 2008-12-31
EA017187B1 (ru) 2012-10-30
ES2416364T3 (es) 2013-07-31

Similar Documents

Publication Publication Date Title
EA201000038A1 (ru) Конденсированные производные тиазола в качестве ингибиторов киназ
MY146387A (en) Thieno-pyridine derivatives as mek inhibitors
ATE526021T1 (de) Kondensierte thiazol-derivate als kinase-hemmer
NI201800141A (es) Moduladores alostéricos positivos del receptor muscarínico de acetilcolina m4
MX2010001218A (es) Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos.
SMT201600089B (it) Composti di 3,4-diidropirazino[2,3-b]pirazin-2(1 h)-one come inibitori di chinasi mtor per indicazioni oncologiche e malattie associate al percorso mtor/p13k/akt
CL2008003280A1 (es) Compuestos derivados de 1h-pirazolo[3,4-b]piridina)-4-aril sustituidas; la composicion farmaceutica que los contiene; y sus procesos de preparacion.
BR112016011484A2 (pt) Derivados de imidazopirimidina como moduladores de atividade de tnf
EP3489238B8 (en) Pharmaceutical compositions of 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and [1,2,4]triazolo[1,5-c]pteridin-5(6h)-one derivatives as pde1 inhibitors for treating e.g. neurological disorders
MX380578B (es) Derivados de imidazol pentaciclicos fusionados.
BRPI0722088A2 (pt) derivados de pirrolo[2,3-b]piridina como moduladores de cinase
EP3542629A3 (en) Dithiol compounds, derivatives, and uses therefor
WO2008020206A3 (en) Fused thiophene derivatives as mek inhibitors
MY152386A (en) Substituted 6a,7,8,9-tetrahydropyrido[3,2-e] pyrrolo[1,2-a]pyrazin-6(5h)-ones
BR112016012243A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
GT201400213A (es) Inhibidores de diacilglicerol aciltransferasa 2
HUE036953T2 (hu) 2,3-dihidro-benzo[1,4]oxazin-származékok és rokon vegyületek, mint foszfoinozitid-3-kináz (PI3K) inhibitorok például reumatoid arthritis kezelésére
CL2012001027A1 (es) Compuestos derivados de 7-(fenilamina)-5-oxo-1,2,3,5-tetrahidro-imidazo[1,2-a]piridina, 7-(fenilamina)5-oxo-2,3-dihidro-5h-tiazolo[3,2-a]piridina, 7-(fenulaminas)-5-oxo-2,3-dihidro-2hoxazolo[3,2-a]piridina: composicion farmaceutica; utiles en el tratamiento de enfermedades, trastornos o sindrome asociado con la inhibicion mek.
CO6220934A2 (es) Derivados de imidazolidinacaboxamida como inhibidores de lipasas y foffolipasas
BR112016029635A2 (pt) derivados pirazolo-piridina como inibidores de quinase
BR112016012254A2 (pt) Derivados de triazolpiridazina como moduladores de atividade de tnf
PT1622569E (pt) Derivados de aza espiro alcanos como inibidores de metaloproteases
TW200745137A (en) Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
IN2015DN03751A (enExample)
UA99469C2 (ru) Конденсированные производные тиазола как ингибиторы киназы

Legal Events

Date Code Title Description
FG Application granted